Key takeaways for Vermont
- • Wegovy (semaglutide) is FDA-approved for MASH with F2–F3 fibrosis (Aug 2025) — the first GLP-1 approved for a liver disease.
- • The approval was based on the phase 3 ESSENCE trial (MASH resolution + fibrosis improvement endpoints met).
- • Resmetirom (Rezdiffra) was the first MASH-specific drug (2024); Wegovy followed in 2025. Tirzepatide is promising but not yet MASH-approved.
- • Green Mountain Care coverage rules apply for NAFLD / MASLD (Fatty Liver Disease) patients in Vermont — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for NAFLD / MASLD (Fatty Liver Disease)
Wegovy (semaglutide 2.4 mg) was FDA-approved in August 2025 for MASH with moderate-to-advanced (F2–F3) liver fibrosis — the first GLP-1 approved for a liver disease — based on the phase 3 ESSENCE trial (MASH resolution and fibrosis-improvement endpoints met). Resmetirom (Rezdiffra) was the first MASH-specific drug (approved 2024). Tirzepatide showed similar liver-fat and fibrosis improvements in SYNERGY-NASH but is not yet FDA-approved for MASH. Evidence grade: A (phase 3 RCT for semaglutide). Outside the Wegovy MASH indication, GLP-1s are used off-label or based on coexisting obesity/T2D indications.
Vermont-specific context
Vermont has telehealth access concentrated in Burlington, South Burlington, Rutland metros, with additional reach to Essex Junction and Bennington. University of Vermont Medical Center is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.healthvermont.gov.
Vermonttelehealth & pricing rules
- • Vermont requires a live video consultation before a GLP-1 prescription.